DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RELISTOR
» See Plans and Pricing
All Clinical Trials for Relistor
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00804141 | Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation | Completed | Pfizer | Phase 3 | 2008-12-01 | This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period. |
| NCT00804141 | Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation | Completed | Valeant Pharmaceuticals International, Inc. | Phase 3 | 2008-12-01 | This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period. |
| NCT00949377 | Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department? | Withdrawn | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2009-09-01 | The investigators want to prove that people WITHOUT advanced cancer who are taking opioid medications (for problems like back pain) can receive methylnaltrexone (MNTX) safely. Since the FDA has only approved MNTX for advanced cancer patients, the investigators' research is investigating how MNTX can work for NON-cancer patients. This research is being conducted to prove that MNTX can work for non-cancer patients with opioid related constipation. |
| NCT00949377 | Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department? | Withdrawn | Beth Israel Medical Center | Phase 4 | 2009-09-01 | The investigators want to prove that people WITHOUT advanced cancer who are taking opioid medications (for problems like back pain) can receive methylnaltrexone (MNTX) safely. Since the FDA has only approved MNTX for advanced cancer patients, the investigators' research is investigating how MNTX can work for NON-cancer patients. This research is being conducted to prove that MNTX can work for non-cancer patients with opioid related constipation. |
| NCT01004393 | Methylnaltrexone for Opioid-induced Constipation in Cancer Patients | Completed | University of Vermont | Phase 2 | 2009-10-01 | The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease. |
| NCT01012960 | Opioids and Esophageal Function | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2009-11-01 | The purpose of this study is to evaluate if opioid-induced effects on the pharynx and esophagus is centrally or peripherally mediated. |
| NCT01012960 | Opioids and Esophageal Function | Completed | Region Örebro County | Phase 4 | 2009-11-01 | The purpose of this study is to evaluate if opioid-induced effects on the pharynx and esophagus is centrally or peripherally mediated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Relistor
Condition Name
Clinical Trial Locations for Relistor
Trials by Country
Clinical Trial Progress for Relistor
Clinical Trial Phase
Clinical Trial Sponsors for Relistor
Sponsor Name
